Show threadKonstantin 1d ago
Ärztin Aleid Koppius aus Amsterdam behandelt täglich Patient:innen mit Kaakproblemen. Sie sagt: „Botox ist kein Wundermittel – es lindert Beschwerden, aber beseitigt nicht die Ursache.“ Für viele bleibt es dennoch eine echte Hilfe. #Medizin #Botulinumtoxin 2/
Yonhap Infomax NewsJan 30
Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ExportDeal #MexicoMarket #BotulinumToxin #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102961
Daewoong Pharmaceutical Exports Nabota to Mexico in 29.5 Billion Won Deal

Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.

Yonhap Infomax
Yonhap Infomax NewsJan 15
Hugel Inc. announced plans to reach 900 billion won ($675 million) in annual revenue by 2028, targeting 30% of sales from the US market, with a focus on expanding its botulinum toxin business and maintaining a 50% EBITDA margin.
#YonhapInfomax #HugelInc #AnnualRevenue #USMarket #BotulinumToxin #EBITDAMargin #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100165
Hugel Targets 900 Billion Won in Annual Revenue by 2028—Aims for 30% of Sales from US Market

Hugel Inc. announced plans to reach 900 billion won ($675 million) in annual revenue by 2028, targeting 30% of sales from the US market, with a focus on expanding its botulinum toxin business and maintaining a 50% EBITDA margin.

Yonhap Infomax
unitedvrg.comJan 15
Botulinum Toxins in Clinical Aesthetic Practice Third Edition Volume One: Clinical Adaptations (2018) by Dr. Anthony V. Benedetto, DO, FACP
Author: Botulinum Toxin
File Type: PDF
Download at https://unitedvrg.com/2024/03/09/pdf-botulinum-toxins-in-clinical-aesthetic-practice-third-edition-volume-one-clinical-adaptations-2018-by-dr-anthony-v-benedetto-do-facp/
#Aesthesia, #BotulinumToxin
unitedvrg.comDec 3
Botulinum Neurotoxin Injection Manual - Alter, Katharine E 2015 (2014) by Katharine E Alter
Author: Botulinum Toxin
File Type: PDF
Download at https://unitedvrg.com/2022/05/28/pdf-botulinum-neurotoxin-injection-manual-alter-katharine-e-2015-2014-by-katharine-e-alter/
#Dermatology, #BotulinumToxin
ra schmiNov 9
Zu viel ...

War gestern in #Essen-Werden. Bei schönem #Wetter war da für mich von Einigem zu viel:

#Pelze
#SUV
#Botulinumtoxin

Nicht meine meine #Welt.
Yonhap Infomax NewsSep 29
Daewoong Pharmaceutical has expanded its botulinum toxin Nabota to 10 Middle Eastern countries, securing new export deals with Iraq and Bahrain as part of its broader MENA strategy.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #MiddleEast #ExportContracts #BotulinumToxin #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=83824
Daewoong Pharmaceutical's Nabota Completes Entry into 10 Middle Eastern Countries

Daewoong Pharmaceutical has expanded its botulinum toxin Nabota to 10 Middle Eastern countries, securing new export deals with Iraq and Bahrain as part of its broader MENA strategy.

Yonhap Infomax
taegaSep 23

Discovering Facial Slimming Botulinum Toxin Specialists at TAEGA in Melbourne
In Melbourne, TAEGA stands out as a renowned center for facial slimming, especially botulinum toxin for jaw clenching.

Website: https://taega.com.au/botulinum-toxin-for-jaw-clenching-melbourne/
#taega #botulinumtoxin #toxin #jawclenching

Yonhap Infomax NewsJul 30, 2025
Daewoong Pharmaceutical has voluntarily withdrawn its application for Nabota's 100-unit product approval in China, aiming to resubmit with expanded dosage options to meet regulatory and market demands.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ChinaApproval #BotulinumToxin #ProductWithdrawal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=74601
Daewoong Pharmaceutical Voluntarily Withdraws Nabota Product Application in China

Daewoong Pharmaceutical has voluntarily withdrawn its application for Nabota's 100-unit product approval in China, aiming to resubmit with expanded dosage options to meet regulatory and market demands.

Yonhap Infomax
ScienceOpenJul 3, 2025

'Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders' - a new article in 'Neuropharmacology and Therapy' on #ScienceOpen:

🔎 https://www.scienceopen.com/hosted-document?doi=10.15212/npt-2024-0014

🖇️ #Neuropharmacology #Neurology #BotulinumToxin #NeurologicalDisorders

Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d34732e145">BoNT type A (BoNT-A) is a neurotoxic protein produced by the anaerobic bacterium Clostridium botulinum. In recent years, BoNT-A has demonstrated substantial efficacy in the management of various diseases, particularly neurological disorders, and has served as a versatile therapeutic agent in modern medicine. This review is aimed at comprehensively examining the application of BoNT-A in various non-dystonia disorders—including hyperhidrosis, salivation, chronic migraine, trigeminal neuralgia, postherpetic neuralgia, primary tremor, depression, and Parkinson’s disease—in the field of neurology. </p>

ScienceOpen